8-K 1 tm2037823d1_8k.htm FORM 8-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 7, 2020

 

HOOKIPA PHARMA INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware 001-38869 81-5395687

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

     
350 Fifth Avenue, 72nd Floor, Suite
7240
   
New York, New York   10118
(Address of principal executive offices)   (zip code)
     

Registrant’s telephone number, including area code: +43 1 890 63 60

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
   

Securities registered pursuant to Section 12(b) of the Act:

     
Title of each class Trading Symbol(s) Name of exchange on which registered
Common stock, $0.0001 HOOK The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On December 7, 2020, HOOKIPA Pharma Inc. (the “Company”) announced positive interim data from its ongoing Phase 1 clinical trial of HB-201, its replicating monotherapy candidate for the treatment of HPV16+ cancers. A copy of the press release is attached hereto as Exhibit 99.1.

 

The information in this Item 7.01 of Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

 

Item 8.01 Other Events.

 

During a conference call and webcast scheduled to be held at 8:30 a.m. Eastern Time on December 7, 2020, the Company’s management will discuss the Phase 1 data for HB-201. The slide presentation for the conference call and webcast is filed as Exhibit 99.2 hereto and is incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

  Description
99.1   Press release issued by HOOKIPA Pharma Inc. on December 7, 2020
99.2   HOOKIPA Pharma Inc. Investor Presentation dated December 7, 2020

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  HOOKIPA Pharma Inc.
     
Date: December 7, 2020 By: /s/ Jörn Aldag
    Jörn Aldag
    Chief Executive Officer
    (Principal Executive Officer)

 

2